Evidence map›Paper›PMID 41488589›Full record

ArticleAPL bioengineering2025

Formononetin suppresses osteosarcoma by targeting MYO1B and remodeling the tumor immune microenvironment.

Yun Liu, Liang Xiong, Wenyu Feng, Tianyu Xie, Jiming Liang, Mingxiu Yang, Shanhang Li, Kai Luo, Feicui Li, Shengping Tang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yun LiuDepartment of Spine and Bone Disease, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.ORCID https://orcid.org/0000-0002-7745-1083
Liang XiongDepartment of Traumatic Orthopaedic, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Wenyu FengDepartment of Orthopaedic, The Second Affiliated Hospital of Guangxi Medical University, 530005 Nanning, China.
Tianyu XieDepartment of Traumatic Orthopaedic, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Jiming LiangDepartment of Spine and Bone Disease, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Mingxiu YangDepartment of Spine and Bone Disease, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Shanhang LiDepartment of Bone and Soft Tissue, The Affiliated Tumour Hospital of Guangxi Medical University, 530021 Nanning, China.
Kai LuoDepartment of Spine and Bone Disease, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Feicui LiDepartment of Spine and Bone Disease, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Shengping TangDepartment of Traumatic Orthopaedic, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Shangyu LiuDepartment of Spine and Bone Disease, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.ORCID https://orcid.org/0009-0009-4453-784X
Qian HuangDepartment of Traumatic Orthopaedic, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.ORCID https://orcid.org/0000-0002-0932-5181
Shijie LiaoDepartment of Traumatic Orthopaedic, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Jianhong LiuDepartment of Traumatic Orthopaedic, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.ORCID https://orcid.org/0009-0007-2010-6901
Yangjie CaiDepartment of Traumatic Orthopaedic, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Qingjun WeiDepartment of Orthopaedic, The Second Affiliated Hospital of Guangxi Medical University, 530005 Nanning, China.
Haijun TangDepartment of Spine and Bone Disease, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Fuxing TangORCID https://orcid.org/0009-0002-5122-1869

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to and associated toxic side effects of neoadjuvant chemotherapy remain major obstacles to improving the prognosis of osteosarcoma patients. Consequently, there is an urgent need to discover effective therapeutic agents with lower toxicity. In this study, the patient-derived xenograft (PDX) model was established and single-cell multi-omics sequencing was performed to comprehensively analyze changes in cellular heterogeneity and gene expression patterns of under formononetin treatment. We found that formononetin can significantly inhibit tumor growth in the osteosarcoma PDX model, on which the single-cell sequencing identified MYO1B as a key target mediating the anti-osteosarcoma effects of formononetin.

Identifiers

PMID41488589
PMCPMC12757119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.